Role of cystatin C in the assessment of renal function and its relationship with cardiovascular risk;Papel de la cistatina C en la valoración de la función renal y su relación con el riesgo cardiovascular

Hipertension

Volumn 24, Issue 5, 2007, Pages 201-208

  Robles, N R ^a   Barroso, S ^a   Ruiz Calero, R ^a  

^a HOSPITAL INFANTA CRISTINA   (Spain)

Author keywords

Cardiovascular risk; Cystatin; Renal function

Indexed keywords

CREATININE; STEFIN A;

CARDIOVASCULAR RISK; CHRONIC KIDNEY FAILURE; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DISEASE MARKER; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY DISEASE; KIDNEY FUNCTION; MORBIDITY; MORTALITY; PROGNOSIS; REVIEW;

EID: 35048857919     PISSN: 02128241     EISSN: 15782115     Source Type: Journal    
DOI: 10.1016/S0212-8241(07)75755-9     Document Type: Review

References (77)

1. Chasis H, Smith HW. The excretion of urea in normal man and in subjects with glomerulonephritis. J Clin Invest. 1938;17:347-58.
2. Steinitz K, Türkand H. The determination of the glomerular filtration by the endogenous creatinine clearance. J Clin Invest. 1940;19:285-98.
3. Rodrigo E, de Francisco ALM, Arias M. Medida de la función renal en consulta de Atención Primaria. Nefrología Extrahospitalaria. 2002;3:23-8.
4. James GD, Sealey JE, Alderman M, Ljungman S, Mueller FB, Pecker MS, et al. A longitudinal study of urinary creatinine and creatinine clearance in normal subjects: race, sex, and age differences. Am J Hypertens. 1988;1:124-31.
5. Heymsfield SB, Arteaga C, McManus C, Smith J, Moffitt S. Measurement of muscle mass in humans: validity of the 24 hour urinary creatinine method. Am J Clin Nutr. 1983;37:478-94.
6. Levey AS, Berg RL, Gassman JJ, Hall PM, Walker WG. Creatinine filtration, secretion and excretion during progressive renal disease. Kidney Int. 1989;36 Suppl 27:S73-80.
7. Young DS. Effects of Drugs on Clinical Laboratory Tests, 3rd ed. Washington, DC: American Association for Clinical Chemistry Press; 1990.
8. Norden G, Björck S, Granerus G, Nyberg G. Estimation of renal function in diabetic nephropathy-comparison of five methods. Nephron. 1987;47:36-42.
9. Rowe JW, Andres R, Tobin JD, Norris AH, Shock NW. The effect of age on creatinine clearance in men: A cross-sectional and longitudinal study. J Gerontol. 1976;31:155-63.
10. Davies DF, Shock NW. Age changes in glomerular filtration rate, effective renal plasma flow and tubular excretory capacity in adult males. J Clin Invest. 1950;29:496-507.
11. Arias M. Estudio de la función renal. Nefrología clínica. Madrid: Editorial Panamericana; 1998.
12. Fuller NJ, Elia M. Factors influencing the production of creatinine: Implications for the determination and interpretation of urinary creatinine and creatine in man. Clin Chim Acta. 1988;175:199-210.
13. Jelliffe RW, Jelliffe SM. Estimation of creatinine clearance from changing serumcreatinine levels. Lancet. 1971;2:710.
14. Cockroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31-41.
15. 99Tc] DTPA clearance and the approximation of Cockroft and Gault. Aust NZ J Med. 1993;23:494-7.
16. • Levey AS, Bosch JP, Breyer Lewis J, Greene T, Rogers N, Roth D, for the Modification of Diet in Renal Disease Study Group. A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation. Ann Intern Med. 1999;130:461-70.
17. • Laterza OF, Price CP, Scott MG. Cystatin C: an improved estimator of glomerular filtration rate? Clin Chem. 2002;48:699-707.
18. Newman DJ. Cystatin C. Ann Clin Biochem. 2002;39:89-104.
19. Dharnidharka VR, Charles Kwon C, Stevens G. Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am J Kidney Dis. 2002;40:221-6.
20. Coll E, Botey A, Álvarez L, Poch E, Quinto L, Saurina A, et al. Serum cystatin C as a new marker for noninvasive estimation of glomerular filtration rate and as a marker for early renal impairment. Am J Kidney Dis. 2000;36:29-34.
21. Oddoze C, Morange S, Portugal H, Berland Y, Dussol B. Cystatin C is not more sensitive than creatinine for detecting early renal impairment in patients with diabetes. Am J Kidney Dis. 2001;38:310-6.
22. Van Den Noortgate NJ, Janssens WH, Delanghe JR, Afschrift MB, Lameire NH. Serum cystatin C concentration compared with other markers of glomerular filtration rate in the old old. J Am Geriatr Soc. 2002;50:1278-82.
23. Risch L, Huber AR. Assessing glomerular filtration rate in renal transplant recipients by estimates derived from serum measurements of creatinine and cystatin C. Clin Chim Acta. 2005;356:204-11.
24. Rule AD, Bergstralh EJ, Slezak JM, Bergert J, Larson TS. Glomerular filtration rate estimated by cystatin C among different clinical presentations. Kidney Int. 2006;69:399-405.
25. Hoek FJ, Kemperman FA, Krediet RT. A comparison between cystatin C, plasma creatinine and the Cockcroft and Gault formula for the estimation of glomerular filtration rate. Nephrol Dial Transplant. 2003;18:2024-31.
26. Filler G, Lepage N. Should the Schwartz formula for estimation of GFR be replaced by cystatin C formula? Pediatr Nephrol. 2003;18:981-5.
27. Larsson A, Malm J, Grubb A, Hansson LO. Calculation of glomerular filtration rate expressed in ml/min from plasma cystatin C values in mg/l. Scand J Clin Lab Invest. 2004;64:25-30.
28. Grubb A, Nyman U, Bjork J, Lindstrom V, Rippe B, Sterner G, et al. Simple cystatin C-based prediction equations for glomerular filtration rate compared with the modification of diet in renal disease prediction equation for adults and the Schwartz and the Counahan-Barratt prediction equations for children. Clin Chem. 2005;51:1420-31.
29. Poge U, Gerhardt T, Stoffel-Wagner B, Klehr HU, Sauerbruch T, Woitas RP. Calculation of glomerular filtration rate based on cystatin C in cirrhotic patients. Nephrol Dial Transplant. 2006;21:660-4.
30. White C, Akbari A, Hussain N, Dinh L, Filler G, Lepage N, et al. Estimating glomerular filtration rate in kidney transplantation: a comparison between serum creatinine and cystatin C-based methods. J Am Soc Nephrol. 2005;16:3763-70.
31. Poge U, Gerhardt T, Stoffel-Wagner B, Palmedo H, Klehr HU, Sauerbruch T, et al. Cystatin C-based calculation of glomerular filtration rate in kidney transplant recipients. Kidney Int. 2006;70:204-10.
32. Martin MV, Barroso S, Herraez O, De Sande F, Caravaca F. Cistatina C como estimador de la función renal en estadios avanzados de enfermedad renal crónica. Nefrología. 2006;26:433-8.
33. Christensson AG, Grubb AO, Nilsson JA, Norrgren K, Sterner G, Sundkvist G. Serum cystatin C advantageous compared with serum creatinine in the detection of mild but not severe diabetic nephropathy. J Intern Med. 2004;256:510-8.
34. • Knight EL, Verhave JC, Spiegelman D, Hillege HL, de Zeeuw D, Curhan GC, et al. Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement. Kidney Int. 2004;65:1416-21.
35. Galteau MM, Guyon M, Gueguen R, Siest G. Determination of serum cystatin C: biological variation and reference values. Clin Chem Lab Med. 2001;39:850-7.
36. Wiesli P, Schwegler B, Spinas GA, Schmid C. Serum cystatin C is sensitive to small changes in thyroid function. Clin Chim Acta. 2003;338:87-90.
37. Fricker M, Wiesli P, Brandle M, Schwegler B, Schmid C. Impact of thyroid dysfunction on serum cystatin C. Kidney Int. 2003;63:1944-7.
38. Takeuchi M, Fukuda Y, Nakano I, Katano Y, Hayakawa T. Elevation of serum cystatin C concentrations in patients with chronic liver disease. Eur J Gastroenterol Hepatol. 2001;13:951-5.
39. Kos J, Stabuc B, Cimerman N, Brunner N. Serum cystatin C, a new marker of glomerular filtration rate, is increased during malignant progression. Clin Chem. 1998;44:2556-7.
40. Segura de la Morena J, García Donaire JA, Ruilope Urioste LM. Relevancia de la insuficiencia renal en el pronóstico cardiovascular de los pacientes con hipertensión arterial esencial. Med Clin (Barc). 2004;123:143-8.
41. Shulman NB, Ford CE, Hall WD, Blaufox MD, Simon D, Langford HG, et al. Prognostic value of serum creatinine and effect of treatment of hypertension on renal function. Results from the Hypertension Detection and Follow-up Program. Hypertension. 1989;13 Suppl 5:80-93.
42. • Ruilope LM, Salvetti A, Jamerson K, Hansson L, Warnold I, Wedel H, et al. Renal function and intensive lowering of blood pressure in the hypertensive subjects of the Hypertension Optimal Treatment (HOT) study. J Am Soc Nephrol. 2001;12:218-25.
43. •• Zanchetti A, Hansson L, Dahlöf B, Elmfeldt D, Kjeldsen S, Kolloch R, et al on behalf of the HOT Study Group. Effects of individual risk factors on the incidence of cardiovascular events in the treated hypertensive patients of the Hypertension Optimal Treatment Study. J Hypertens. 2001;9:1149-59.
44. • Ruilope LM, Palmer C, De Leeuw P, Morris BJ, Castaigne A, Rosenthal T, et al. Evaluation of different parameters of renal function as predictors of primary outcome in the INSIGHT study [resumen]. J Hypertens. 2001;19 Suppl 2:223.
45. De Leeuw P, Thijs L, Birkenhager WH, Voyaki S, Efstratopoulos AD, Fagard R, et al. Prognostic significance of renal function in elderly patients with isolated systolic hypertension: results from Syst-Eur trial. J Am Soc Nephrol. 2002;13:2213-22.
46. Wang JG, Staessen JA, Fagard RH, Birkenhager WH, Gong L, Liu L. Prognostic significance of serum creatinine and uric acid in older Chinese patients with isolated systolic hypertension. Hypertension. 2001;37:1069-74.
47. Pahor M, Shorr RI, Somes GW, Cushman WC, Ferrucci L, Bailey JE, et al. Diuretic-based treatment and cardiovascular events in patients with mild renal dysfunction enrolled in the systolic in the elderly program. Arch Intern Med. 1998;158:1340-5.
48. Mann JFE, Gerstein HC, Pogue J, Bosch J, Yusuf S. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med. 2001;134:629-36.
49. •• Schillaci G, Reboldi G, Verdecchia P. High-normal serum creatinine concentration is a predictor of cardiovascular risk in essential hypertension. Arch Intern Med. 2001;161:886-91.
50. Culleton BF, Larson MG, Wilson PW, Evans JC, Parfrey PS, Levy D. Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency. Kidney Int. 1999;56:2214-9.
51. •• Coresh J, Wei GL, McQuillan G, Brancati FL, Levey AS, Jones C, et al. Prevalence of high blood pressure and elevated serum creatinine level in the United States. Findings from the Third National Health and Nutrition Examination Survey (1988-1994). Arch Intern Med. 2001;161:1207-16.
52. • Kramer HJ, Nguyen QD, Curhan G, Hsu C. Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus. JAMA. 2003;289:3273-7.
53. Shlipak MG, Fried LF, Stehman-Breen C, Siscovick D, Newman AB. Chronic renal insufficiency and cardiovascular events in the elderly: findings from the Cardiovascular Health Study. Am J Geriatr Cardiol. 2004;13:81-90.
54. • Manjunath G, Tighiouart H, Ibrahim H, MacLeod B, Salem DN, Griffith JL, et al. Level of kidney functions as a risk factor for atherosclerotic cardiovascular outcomes in the community. J Am Coll Cardiol. 2003;41:47-55.
55. Henry RMA, Kostense PJ, Bos G, Dekker JM, Nijpels G, Heine RJ, et al. Mild renal insufficiency is associated with increased cardiovascular mortality: the Hoorn Study. Kidney Int. 2002;62:1402-7.
56. •• Redon J, Cea-Calvo L, Lozano JV, Fernández- Pérez C, Navarro J, Bonet A, et al; on behalf of the investigators of the ERIC-HTA 2003 Study. Kidney function and cardiovascular disease in the hypertensive population: the ERIC-HTA study. J Hypertens. 2006;24:663-9.
57. Herrero P, Marín R, Fernández Vega F, Gorostidi M, Riesgo A, Vázquez J, et al; en representación de los investigadores del estudio FRESHA. Función renal y riesgo cardiovascular en pacientes con hipertensión arterial esencial. Estudio FRESHA. Nefrologia. 2006;28:330-8.
58. Watanabe S, Okura T, Liu J, Miyoshi K, Fukuoka T, Hiwada K, et al. Serum Cystatin C Level Is a Marker of End-Organ Damage in Patients with Essential Hypertension. Hypertens Res. 2003;26:895-9.
59. •• Shlipak MG, Sarnak MJ, Katz R, Fried LF, Seliger SL, Newman AB, et al. Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med. 2005;352:2049-60.
60. Fried LF, Katz R, Sarnak MJ, Shlipak MG, Chaves PH, Jenny NS, et al. Kidney function as a predictor of noncardiovascular mortality. J Am Soc Nephrol. 2005;16:3728-35.
61. •• Shlipak MG, Sarnak MJ, Katz R, Fried LF, Seliger SL, Newman AB, et al. Cystatin-C and Mortality in Elderly Persons With Heart Failure. J Am Coll Cardiol. 2005;45:268-71.
62. •• Sarnak MJ, Katz R, Stehman-Breen CO, Fried LF, Jenny NS, Psaty BM, et al. Cystatin C Concentration as a Risk Factor for Heart Failure in Older Adults. Ann Intern Med. 2005; 142:497-505.
63. • Shlipak MG, Katz R, Sarnak MJ, Fried LF, Newman AB, Stehman-Breen C, et al. Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease. Ann Intern Med. 2006;145:237-46.
64. • Seliger SL, Longstreth WT Jr, Katz R, Manolio T, Fried LF, Shlipak M, et al. Cystatin C and subclinical brain infarction. J Am Soc Nephrol. 2005;16:3721-7.
65. O'Hare AM, Newman AB, Katz R, Fried LF, Stehman-Breen CO, Seliger SL, et al. Cystatin C and incident peripheral arterial disease events in the elderly: results from the Cardiovascular Health Study. Arch Intern Med. 2005;165:2666-70.
66. Shlipak MG, Katz R, Cushman M, Sarnak MJ, Stehman-Breen C, Psaty BM, et al. Cystatin-C and inflammatory markers in the ambulatory elderly. Am J Med. 2005;118:1416.
67. •• Shlipak MG, Wassel Fyr CL, Chertow GM, Harris TB, Kritchevsky SB, Tylavsky FA, et al. Cystatin C and mortality risk in the elderly: the health, aging, and body composition study. J Am Soc Nephrol. 2006;17:254-61.
68. Larsson A, Helmersson J, Hansson LO, Basu S. Increased serum cystatin C is associated with increased mortality in elderly men. Scand J Clin Lab Invest. 2005;65:301-5.
69. •• Koenig W, Twardella D, Brenner H, Rothenbacher D. Plasma concentrations of cystatin C in patients with coronary heart disease and risk for secondary cardiovascular events: more than simply a marker of glomerular filtration rate. Clin Chem. 2005;51:321-7.
70. •• Jernberg T, Lindahl B, James S, Larsson A, Hansson LO, Wallentin L. Cystatin C: a novel predictor of outcome in suspected or confirmed non-ST-elevation acute coronary syndrome. Circulation. 2004;110:2342-8.
71. Albert MA, Rifai N, Ridker PM. Plasma levels of cystatin-C and mannose binding protein are not associated with risk of developing systemic atherosclerosis. Vasc Med. 2001;6:145-9.
72. Peralta CA, Whooley MA, Ix JH, Shlipak MG. Kidney function and systolic blood pressure new insights from cystatin C: data from the Heart and Soul Study. Am J Hypertens. 2006;19:939-46.
73. Ozmen B, Ozmen D, Turgan N, Habif S, Mutaf I, Bayindir O. Association between homocysteinemia and renal function in patients with type 2 diabetes mellitus. Ann Clin Lab Sci. 2002;32:279-86.
74. Wilcken DE, Wang J, Sim AS, Green K, Wilcken B. Asymmetric dimethylarginine in homocystinuria due to cystathionine beta-synthase deficiency: relevance of renal function. J Inherit Metab Dis. 2006;29:30-7.
75. Abdella N, Mojiminiyi OA, Akanji AO. Homocysteine and endogenous markers of renal function in type 2 diabetic patients without coronary heart disease. Diabetes Res Clin Pract. 2000;50:177-85.
76. Robles NR, Romero J, Gómez Casero L, Escola JM, Ramos Salado JL, Sánchez Casado E. Hyperhomocysteinemia in chronic kidney patients with mild renal failure. Eur J Intern Med. 2005;16:334-8.
77. • Bostom AG, Bausserman L, Jacques PF, Liaugaudas G, Selhub J, Rosenberg IH. Cystatin C as a Determinant of Fasting Plasma Total Homocysteine Levels in Coronary Artery Disease Patients With Normal Serum Creatinine. Arterioscler Thromb Vasc Biol. 1999;19:2241-4.